SCHEMBL5137978

SCHEMBL5137978

COc1cccc(C(=O)N(Cc2ccc(C)cc2)C2Cc3ccccc3C2)c1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
ATM Q13315 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
HTR2A P28223 1/20 0.44
MAPT P10636 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
GAA P10253 1/20 0.41
MAPK1 P28482 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
HPGD P15428 1/20 0.39
NAMPT P43490 1/20 0.39
SLC6A12 P48065 1/20 0.39
KDM4E B2RXH2 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136969 0.91 TSHR (0.48) TSHRSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL5137304 0.85 SMN1; SMN2 (0.41) TSHRSMN1; SMN2L3MBTL1MAPTMEN1
SCHEMBL5135704 0.80 KMT2A (0.45) TSHRSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL5136129 0.79 HTR2A (0.46) TSHRSMN1; SMN2L3MBTL1HTR2AMAPT
SCHEMBL5373300 0.79 MEN1 (0.46) TSHRSMN1; SMN2HTR2AMEN1KMT2A
SCHEMBL5135771 0.78 MEN1 (0.51) TSHRSMN1; SMN2HTR2AMEN1KMT2A
SCHEMBL6388406 0.77 HTR2A (0.45) TSHRSMN1; SMN2HTR2AMAPTMEN1
SCHEMBL5358561 0.77 ALDH1A1 (0.47) TSHRSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL5074889 0.76 HTR2A (0.41) TSHRSMN1; SMN2HTR2AMAPTGAA
SCHEMBL5361344 0.76 ALDH1A1 (0.46) TSHRSMN1; SMN2HTR2AMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed